Research on prostate cancer biology, detection, and outcomes. Covers genetic clues, DNA damage, diet and survival, and screening awareness.
Hong Kong Metropolitan University (HKMU) has achieved its first-ever technology licensing agreement with a UK-based healthcare company. The know-how licensing agreement is for a non-invasive electrochemical screening technology that offers a promising method for early detection of prostate cancer through a simple urine test.
Researchers at Uppsala University have developed an AI system that can detect subtle tissue changes indicative of prostate cancer, missing it from human pathologists. The study found the AI detected cancers in over 80% of cases where pathologists missed them.
A new 'dual-mode' tracer agent shows promise in helping surgeons image and plan prostate cancer procedures while also providing guided surgery with real-time radiation detection. The tracer targets PSMA, a protein highly expressed on prostate cancer cells, offering high-resolution visual guidance and targeted radiation density detection.
Scientists have developed a monoclonal antibody to combat life-threatening inflammatory diseases like sepsis and ARDS. The antibody shows promise in blocking the immune system's hyperactive response and restoring healthy function without unwanted side effects.
A new study from Denmark shows that men with biochemically recurrent prostate cancer who undergo PSMA PET/CT before salvage radiotherapy have improved survival rates compared to those who do not. This research confirms that PSMA PET/CT is a valuable tool for identifying patients likely to benefit from salvage radiotherapy, potentially ...
Motolani Adedipe, a University of Oklahoma professor, has been awarded a Fulbright to conduct research on improving quality of life for prostate cancer survivors in South Korea. Her mixed-methods approach focuses on community engagement and will inform digital health innovation.
Researchers found that RSPO2 amplification is associated with poor outcomes in PC patients and promotes genes and signaling pathways associated with aggressive PC. The study highlights RSPO2 as a key driver of disease progression and opens new possibilities for treatment strategies.
A new study found that one in six men with low-grade prostate cancer (GG1) actually have intermediate- or high-risk cancer when other clinical features are considered. This suggests that relying on biopsy grade alone can lead to underestimating disease risk and misclassifying individuals who may benefit from definitive treatment.
This study used SILAC-based quantitative proteomics to investigate the impact of missense mutations on protein expression in prostate cancer versus healthy tissues. The results show that missense mutations correlate with changes in protein abundance, and specific mutations have deleterious effects on protein stability and function.
Recent AI-based models, such as Asian Prostate Cancer Artificial Intelligence and Galen Prostate, optimize screening and reduce unnecessary biopsies. These models use multimodal clinical parameters and convolutional neural networks to detect prostate cancer and identify aggressiveness of cancer cells.
A recent study by JAMA Network Open reveals racial differences in care quality among men with newly diagnosed prostate cancer. Black men had lower odds of overtreatment, suggesting better care, while having lower odds of confirmatory testing on active surveillance, indicating worse care.
Researchers have found that a lower dose of abiraterone acetate, 500 mg daily, is as effective in treating prostate cancer as the standard regimen, but with fewer side effects. The study involved nine men with metastatic prostate cancer and showed comparable cancer suppression through reduced PSA levels and hormone suppression.
City of Hope research demonstrates a new drug combination that slows advanced prostate cancer growth without improving overall survival. A novel AI conversation tool helps scientists uncover gene-disease connections without programming expertise.
Researchers at MURR have optimized Terbium-161 for radiopharmaceutical use, enabling targeted destruction of cancer cells with high-energy electrons. The breakthrough could add extra therapeutic effectiveness to existing treatments without requiring new drug development.
Researchers found that prostate cancer cells store fats in lipid droplets under low oxygen conditions, making them less vulnerable to ferroptosis. This adaptation allows cancer cells to evade therapies designed to trigger cell death.
A new study from Uppsala University found that most men with prostate cancer who receive recommended treatment have a good prognosis, with a lower risk of dying from prostate cancer than other causes. The study's findings highlight the importance of assessing a patient's life expectancy in choosing an appropriate treatment strategy.
A study of 62,839 people diagnosed with non-metastatic prostate cancer in Sweden found that those treated according to NCCN Guidelines were likely to survive their cancer for their remaining life-expectancy. Those with low- and intermediate-risk cancer were six times more likely to die of other causes than prostate cancer.
A new study from the University of Michigan Rogel Cancer Center identifies a cellular signature that explains why about one-third of prostate cancers respond especially poorly to treatment. The researchers found that docetaxel could be a good option earlier on in patients whose tumor harbors a specific gene program linked to extreme no...
Researchers identify tumor-associated macrophages that shield tumors from attack and promote metastasis in advanced prostate cancer. Blocking these cells with anti-SPP1 treatment boosts the immune response, slowing cancer progression.
Sylvester researchers found that alcohol-related cancer deaths increased by nearly double from 1990 to 2021, primarily affecting men over 55. A new four-drug combination has been shown to be highly effective and safe in treating patients with newly diagnosed multiple myeloma.
The Association for Molecular Pathology publishes guidelines for detecting homologous recombination deficiency (HRD) in cancer. The report includes recommendations for clinical laboratories, addressing technical aspects of genomic instability and HRD analysis.
A dual-protective approach using Botox and an anti-nausea patch significantly reduces salivary gland toxicity in prostate cancer patients undergoing PSMA-targeted radiopharmaceutical therapy. This strategy led to a 30% decrease in PSMA uptake by the salivary glands without affecting the treatment's cancer-fighting efficacy.
Researchers found that low-cost genetic testing methods can effectively detect BRCA2 and HOXB13 mutations linked to increased prostate cancer risk. These findings support the adoption of precision medicine in prostate cancer care, enabling better diagnosis and personalized treatment plans.
Scientists at MSK found that certain metabolites play a key role in driving differentiation in stem cells, potentially leading to improved tissue regeneration and healing for conditions involving chronic inflammation. APOBEC3 enzymes were linked to breast cancer resistance and growth, with implications for treatment.
Researchers found that it took 13 years for cervical cancer screenings to halve among women over 65, and even longer for prostate cancer screenings to decrease significantly. The study emphasizes the need for more effective tracking mechanisms to identify and reduce inappropriate screening practices.
Researchers at CIC bioGUNE have made a significant breakthrough in understanding the most aggressive form of prostate cancer, revealing that it behaves differently from other types. The study shows that cancer cells use a unique 'language' to communicate with normal cells, altering their behavior and benefiting the tumor.
Researchers identified a novel region in AR that binds to PCNA, and developed a small peptide to mimic this region, blocking the AR-PCNA connection. This approach reduced cancer cell growth, particularly in patients with limited treatment options.
Researchers identified the PROX1 gene as an early driver of prostate cancer aggression, which leads to treatment-resistant tumors. The team found that a class of FDA-approved drugs, HDAC inhibitors, can disable PROX1 and reduce tumor survival in aggressive prostate cancer subtypes.
Acupuncture was found to be an effective treatment for nocturia in survivors of prostate cancer, reducing symptoms comparable to other medications while causing fewer side effects. The study suggests acupuncture may offer a new hope for managing this common issue affecting half of prostate cancer survivors.
Researchers from City of Hope will present novel cancer treatment approaches and combinations, including innovative combination therapies for breast, genitourinary, and gastrointestinal cancers. Additionally, they'll discuss the safety of readministering trastuzumab-deruxtecan to metastatic breast cancer patients with low-grade lung co...
Exosomes carry tumor-derived DNA, RNA, and proteins, enabling a liquid biopsy platform. They enhance diagnostic specificity and sensitivity, and play dual roles—mediating drug resistance and serving as therapeutic vehicles. Exosomal cargo predicts metastatic potential and survival.
Researchers at MD Anderson Cancer Center have made significant discoveries in three key areas of cancer care. In a study on sickle cell disease, the team found that the disorder can suppress immunity by altering DNA structure in CD8+ T cells, leading to potential strategies for improving immunotherapy responses. Meanwhile, a biomarker-...
The University of Texas MD Anderson Cancer Center has been awarded $21.4 million by CPRIT to support cancer research efforts and faculty recruitment. The institution is grateful for the continued funding, which will help advance future potential breakthroughs in cancer treatment.
Christopher Kane's appointment as ABU president reflects his commitment to excellence in patient care, groundbreaking research, and physician mentorship. As president, he will refine certification protocols and enhance the urologist experience.
The study found key differences in tumor biology between non-Hispanic Black and non-Hispanic white veterans, but similar survival outcomes when both groups had equal access to care. The research highlights the importance of broadening access to genomic tools and prioritizing equity in cancer treatment.
Researchers found that stereotactic body radiotherapy (SBRT) is as safe as conventional treatment, with similar side effects and quality of life. SBRT shortens treatment time and may have biological advantages in targeting prostate cancer.
A new AI-based method accurately sorts cancer patients into groups with similar characteristics before treatment and similar outcomes after treatment. The approach showed better performance than standard statistical and machine learning methods in predicting treatment outcomes from health record data.
A new $4 million grant will test whether Prostate Specific Membrane Antigen (PSMA)-Positron Emission Tomography (PET) Computed Tomography (CT) can improve prostate cancer monitoring while reducing screening-related harms. The study aims to reduce the need for biopsies in men with low- or intermediate-risk prostate cancers.
A new study by UCLA researchers shows that advanced MRI imaging and targeted focal therapy can help many men with low- to intermediate-risk prostate cancer safely stay on active surveillance long-term, avoiding follow-up biopsies and delaying or avoiding invasive treatments. The findings suggest that routine follow-up biopsy can now be...
Two new predictive algorithms use health data and blood tests to identify high-risk patients, offering improved accuracy in diagnosing cancers. The models identified additional medical conditions associated with increased cancer risk and new symptoms indicative of multiple cancer types.
A recent study has identified similarities in the mechanisms of diabetes and prostate cancer, suggesting that diabetes drugs like pioglitazone could inhibit tumor growth. Researchers found that PPARγ activation states influence cell behavior, leading to potential new therapeutic approaches for prostate cancer treatment.
A phase III clinical trial has shown that a two-and-a-half week course of precision radiotherapy is equally successful in beating prostate cancer as the standard eight-week approach. After 10 years, both options produced similar disease control rates and survival rates.
Researchers from the University of Southampton engineered a new type of super-strong antibody that triggers a stronger response from the immune system compared to naturally produced antibodies. The study confirms that making subtle increases in rigidity stimulates immune activity, creating a powerful immune response against disease.
Researchers at TUM developed an AI-powered algorithm to predict kidney damage in prostate cancer patients undergoing lutetium-177 PSMA therapy. Early detection could enable personalized treatment adjustments to prevent organ damage.
Researchers at Karolinska Institutet have identified new biomarkers in urine that can indicate the presence and severity of prostate cancer with high precision. The findings surpass current blood biomarker PSA in terms of diagnostic accuracy.
Researchers have discovered genetic properties in prostate cancer that can be targeted to improve patient outcomes, particularly for Chinese men. The findings highlight the potential of precision medicine and more effective treatments.
Hyperbaric oxygen treatment has been shown to provide long-term relief for patients with late radiation-induced injuries, improving symptoms of urinary incontinence, bleeding, and severe pain. The treatment can lead to the healing of chronic injuries and allow patients to live a fully normal life.
A recent preclinical study from Weill Cornell Medicine researchers suggests that three-dimensional gene hubs may promote brain cancer. The findings, published in Molecular Cell, offer a new way to think about cancer beyond gene mutations and highlight the importance of understanding DNA organization in tumor cells.
Researchers from the University of California - Los Angeles Health Sciences will present new research findings on robotic prostate cancer surgery and cost-effectiveness of pembrolizumab in high-risk bladder cancer. The innovations aim to improve patient outcomes and advance the field of urology.
A new study finds that a specific genetic variation in the PTGS2 gene is associated with an increased risk of benign prostate hyperplasia (BPH) in Lebanese men. Men carrying the C version of this gene were more than twice as likely to have BPH compared to those without it.
A UCLA study validates the predictive power of PROSTOX, a genetic test that uses microRNAs to identify patients at higher risk of developing long-lasting urinary side effects from radiation therapy. The test helps doctors and patients choose safer treatment options, reducing the burden of long-term complications.
Researchers discovered TBX2 drives therapy resistance by shifting signaling from the androgen receptor to the glucocorticoid receptor. The study identified a strategy to target this switch, potentially predicting patient risk and offering new treatment approaches.
The national healthcare initiative has been extended for five years to provide world-class healthcare services to every Guyanese citizen. The partnership will establish a national cancer center, modernize national health facilities, and implement an advanced digital health system.
A new study found significant disparities in the use of MRI to detect prostate cancer, with Black patients and those in rural areas having lower rates of diagnostic testing. The study's findings highlight the need for enhanced access to MRI and improved prostate cancer outcomes.
A new surgical technique called NeuroSAFE has been shown to preserve erectile function in men with prostate cancer, with 39% of patients experiencing no or mild dysfunction after treatment. This is compared to 23% of those who received standard surgery.
Researchers mapped m6A patterns across 162 prostate cancer tumors and found that these modifications were closely tied to tumor aggressiveness. Analyzing m6A tags could help doctors predict disease behavior and determine personalized treatment strategies for patients with prostate cancer.
A new study has shown that high-resolution ultrasound can diagnose prostate cancer as effectively as MRI, with improved resolution and lower costs. The technology, called micro-ultrasound, is expected to speed up diagnosis, reduce hospital visits, and make imaging more accessible, particularly in less developed healthcare systems.
A new editorial highlights a growing concern in cancer care: radiotherapy may leave behind residual disease that can lead to worse long-term outcomes. Studies have shown that patients with residual disease are more likely to experience cancer recurrence and shorter survival, emphasizing the need for regular biopsy-based tests.
A sub-analysis of 20-year follow-up data from the European Randomized study of Screening for Prostate Cancer (ERSPC) reveals that men who consistently decline prostate cancer screening appointments have a 45% higher risk of dying from the disease compared to those who attend screening appointments.
A new study confirms that a shorter, higher-dose-per-day radiation course is as effective as conventional radiotherapy for treating early-stage prostate cancer without increasing side effects. The study found similar cancer control rates and fewer gastrointestinal issues with the new approach.